Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11007772rdf:typepubmed:Citationlld:pubmed
pubmed-article:11007772lifeskim:mentionsumls-concept:C0044602lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C0291573lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C0225828lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:11007772lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:11007772pubmed:issue51lld:pubmed
pubmed-article:11007772pubmed:dateCreated2001-1-8lld:pubmed
pubmed-article:11007772pubmed:abstractTextApoptosis of cardiac muscle cells contributes to the development of cardiomyopathy. Recent studies showed that insulin-like growth factor I (IGF-I) inhibits apoptosis of cardiac muscle cells and improves myocardial function in experimental heart failure. This study was carried out to elucidate the role of phosphatidylinositol 3-kinase (PI 3-kinase) in the anti-apoptotic actions of IGF-I in cardiomyocytes and to explore whether expression of constitutively active PI 3-kinase can inhibit apoptosis in cardiomyocytes. Apoptosis of primary cardiomyocytes was induced by doxorubicin treatment and serum withdrawal. Transduction of cardiomyocytes with constitutively active PI 3-kinase specifically lead to serine phosphorylation of Akt, whereas phosphorylation of IGF-I receptor, IRS1/2 and p44/42 mitogen-activated protein kinase were not increased. In the cardiomyocytes transduced with constitutively active PI 3-kinase, activation of the pro-apoptotic caspase 3 was attenuated and fragmentation of DNA was reduced. Preincubating cells with PI 3-kinase inhibitor LY294002 was associated with loss of anti-apoptotic actions of IGF-I and PI 3-kinase. Neither IGF-I nor constitutively active PI 3-kinase lead to serine phosphorylation of Bad, suggesting that the anti-apoptotic effects of PI 3-kinase are not mediated through Bad phosphorylation in cardiac muscle cells. To determine whether activation of caspase 3 is sufficient to induce apoptosis in cardiomyocytes, an engineered TAT-caspase 3 protein was introduced to cardiomyocytes. Significant reduction of cell viability occurred in the cardiomyocytes transduced with active caspase 3, indicating that activation of caspase 3 is sufficient to cause cardiomyocyte death. These findings indicate the existence of an IGF-I receptor-PI 3-kinase-caspase 3 pathway in cardiomyocytes that plays an important role in the anti-apoptotic actions of IGF-I in heart. Moreover, these data suggest that modulation of PI 3-kinase activities may represent a potential therapeutic strategy to counteract the occurrence of apoptosis in cardiomyopathy.lld:pubmed
pubmed-article:11007772pubmed:languageenglld:pubmed
pubmed-article:11007772pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:citationSubsetIMlld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11007772pubmed:statusMEDLINElld:pubmed
pubmed-article:11007772pubmed:monthDeclld:pubmed
pubmed-article:11007772pubmed:issn0021-9258lld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:LeeW LWLlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:ChenDDlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:WuWWlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:DAWH THTlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:JannFFlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:WuY YYYlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:SharmaP MPMlld:pubmed
pubmed-article:11007772pubmed:authorpubmed-author:WangP HPHlld:pubmed
pubmed-article:11007772pubmed:issnTypePrintlld:pubmed
pubmed-article:11007772pubmed:day22lld:pubmed
pubmed-article:11007772pubmed:volume275lld:pubmed
pubmed-article:11007772pubmed:ownerNLMlld:pubmed
pubmed-article:11007772pubmed:authorsCompleteYlld:pubmed
pubmed-article:11007772pubmed:pagination40113-9lld:pubmed
pubmed-article:11007772pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:meshHeadingpubmed-meshheading:11007772...lld:pubmed
pubmed-article:11007772pubmed:year2000lld:pubmed
pubmed-article:11007772pubmed:articleTitleExpression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells.lld:pubmed
pubmed-article:11007772pubmed:affiliationDepartment of Medicine and Biological Chemistry, Division of Endocrinology, Diabetes, and Metabolism, University of California, Irvine, California 92697, USA.lld:pubmed
pubmed-article:11007772pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11007772pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11007772lld:pubmed